Objective To evaluate the efficacy and safety of traditional Chinese medicine (TCM) combined with Western medicine in the treatment of patients with common hand, foot and mouth disease (HFMD) by conducting a prospective, controlled, and randomized trial.
Methods A total of 452 patients with common HFMD were randomly assigned to receive Western medicine alone (n = 220) or combined with TCM (Reduning or Xiyanping injections) (n = 232). The primary outcome was the incidence rate of rash/herpes disappearance within 5 days, while secondary outcomes included the incidence rate for fever, cough, lethargy, agitation, and vomiting clearance within 5 days.
Results The rash/herpes disappearance rate was 45.5% (100/220) in Western medicine therapy group, and 67.2% (156/232) in TCM and Western medicine combined therapy group, with significant difference (P < 0.001). Moreover, TCM remarkably increased the incidence rate of secondary disappearance, which was 56.4% in Western medicine therapy group and 71.4% in TCM and Western medicine combined therapy group (P = 0.001). No drug-related adverse events were observed.
Conclusions It’s suggested that the integrative TCM and Western medicine therapy achieved a better therapeutic efficacy. TCM may become an important complementary therapy on relieving the symptoms of HFMD.
1. Fan X, Jiang J, Liu Y, Huang X, Wang P, Liu L, et al. Detection of human enterovirus 71 and Coxsackievirus A16 in an outbreak of hand, foot, and mouth disease in Henan Province, China in 2009. Virus Genes 2013;46(1):1-9.
2. Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14(12):e1076-1081.
3. Zhu J, Luo Z, Wang J, Xu Z, Chen H, Fan D, et al. Phylogenetic analysis of enterovirus 71 circulating in Beijing, China from 2007 to 2009. PLoS One 2013; 8(2):e56318.
4. Zhang J, Sun J, Chang Z, Zhang W, Wang Z, Feng Z. Characterization of hand, foot, and mouth disease in China between 2008 and 2009. Biomed Environ Sci 2011;24(3):214-221.
5. Zhou H, Guo S, Zhou H, Zhu Y, Zhang L, Zhang W. Clinical characteristics of hand, foot and mouth disease in Harbin and the prediction of severe cases. Chin Med J (Engl) 2012;125(7):1261-1265.
6. Zhu Q, Hao Y, Ma J, Yu S, Wang Y. Surveillance of hand, foot, and mouth disease in mainland China (2008-2009). Biomed Environ Sci 2011;24(4):349-356.
7. Ministry of Health of The People’s Republic of China. Report of epidemic situation of infectious disease in China from January of 2010 to January of 2011. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohjbyfkzj/s3578/201102/50646.htm.
8. Tian H, Yang QZ, Liang J, Dong SY, Liu ZJ, Wang LX. Clinical features and management outcomes of severe hand, foot and mouth disease. Med Princ Pract 2012;21(4):355-359.
9. The Ministry of Health of the People’s Republic of China, Guideline for the Diagnosis and Treatment of Hand Foot and Mouth Disease, Beijing, China, 2010.
10. Xue B, Yao Z, Yu R. Studies on anti-EV71 virus activity of traditional Chinese medicine and its clinical application in treatment of HFMD. Zhongguo Zhong Yao Za Zhi (Chin) 2011;36(23):3366-3370.
11. Lin TY, Liu YC, Jheng JR, Tsai HP, Jan JT, Wong WR, et al. Anti-enterovirus 71 activity screening of chinese herbs with anti-infection and inflammation activities. Am J Chin Med 2009;37(1):143-158.
12. Mu Y, Chen X, Zhang A. Effect of reducing injection on HFMD in children: a randomized controlled trial. Zhongguo Zhong Xi Yi Jie He Za Zhi (Chin) 2011; 31(9):1209-1212.
13. Li X, Zhang C, Shi Q, Yang T, Zhu Q, Tian Y, et al. Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evid Based Complement Alternat Med 2013; 2013:316250.
14. Cao HJ, Liu ZL, Steinmann P, Mu YJ, Luo H, Liu JP. Chinese herbal medicines for treatment of hand, foot and mouth disease: A systematic review of randomized clinical trials. Eur J Integr Med 2012; 4(1):e85-e111.
15. Pharmacopoeia Committee of People’s Republic of China, Chinese Pharmacopoeia, Chemical Industry Press, Beijing, China, 2005 edition, 2005.
16. Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med 2011;155(4):217-225.
17. Zu M, Zhou D, Gao L, Liu A, Du G. Evaluation of Chinese traditional patent medicines against influenza virus in vitro. Yao Xue Xue Bao (Chin) 2010; 45(3):408-412.
18. Lu C, Liu X, Ding X, Chen X, Fan H, Liu Y, et al. A metabolomics profiling study in hand-foot-and-mouth disease and modulated pathways of clinical intervention using liquid chromatography/quadrupole time-of-flight mass spectrometry. Evid Based Complement Alternat Med 2013; 647452.